drugset / Trial / NCT00003495
Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
Current therapies for Stage IV or Recurrent Lung Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage IV or Recurrent Lung Cancer. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with Stage IV or Recurrent Lung Cancer.
Timeline
- Start
- 1996-03-27
- Primary completion
- 2003-11-04
- Completion
- 2003-11-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Astugenal | Unknown | — | Intravenous |
| Subject | antineoplaston A10 | Small molecule | — | Intravenous |
Indications
No indication recorded.